Directed share issue in CELLINK AB (SE) — SEK 1.5 billion

Carnegie acted as joint bookrunner in the directed share issue of new Class B shares at a subscription price of SEK 420 per share. CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries.
March 2021.